Loading...
Prognosis in colon cancer is traditionally determined using the TNM (tumor, node, metastasis) classification system. However, scoring tumor-infiltrating T cells is emerging as a novel prognostic measure.
Now, investigators have conducted an industry-supported, international study to evaluate the prognostic value of a consensus Immunoscore in stage I–III colon cancer (Immunoscore–Colon; HalioDx, France). Of 3539 patient samples processed, 2681 were included in the analysis and used as a training set and as internal and external validation sets. The majority of samples were T3 (66.2%), N0 (70.3%), and stage II (53.5%); 11.3% were DNA mismatch repair (dMMR) deficient. Total T-lymphocyte and cytotoxic T-lymphocyte tumor infiltrates were determin…